Lenalidomide 4'-PEG3-amine

Pricing Availability   Qty
Description: Cereblon ligand with PEG linker and terminal amine for onward chemistry
Chemical Name: 3-[4-[[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethyl]amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-2,6-piperidinedione dihydrochloride
Purity: ≥95% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (2)

Biological Activity for Lenalidomide 4'-PEG3-amine

Lenalidomide 4'-PEG3-amine is a functionalized cereblon ligand for PROTAC® research and development; incorporates an E3 ligase ligand plus a PEG3 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D.

Please contact us for SD files of our available Degrader Building Blocks.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Usage Guidelines for Lenalidomide 4'-PEG3-amine

This product is provided for use in onward chemistry. Suitable solvents can be used.

Technical Data for Lenalidomide 4'-PEG3-amine

M. Wt 507.41
Formula C21H30N4O6.2HCl
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 2624336-87-2
InChI Key ZJNXHHVMOYSOIW-UHFFFAOYSA-N
Smiles NCCOCCOCCOCCNC1=C2CN(C(C2=CC=C1)=O)C3CCC(NC3=O)=O.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Lenalidomide 4'-PEG3-amine

References for Lenalidomide 4'-PEG3-amine

References are publications that support the biological activity of the product.

If you know of a relevant reference for Lenalidomide 4'-PEG3-amine, please let us know.

Keywords: Lenalidomide 4'-PEG3-amine, Lenalidomide 4'-PEG3-amine supplier, PROTAC, cereblon, E3, ubiquitin, ligase, PEG3, linker, conjugate, polyethylene, glycol, terminal, amine, building, blocks, components, Cereblon, Ligands, Plus, Linkers, 7076, Tocris Bioscience

1 Citation for Lenalidomide 4'-PEG3-amine

Citations are publications that use Tocris products. Selected citations for Lenalidomide 4'-PEG3-amine include:

Jason W et al (2019) Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab 29 141-155.e9 PMID: 30174305


Do you know of a great paper that uses Lenalidomide 4'-PEG3-amine from Tocris? Please let us know.

Reviews for Lenalidomide 4'-PEG3-amine

There are currently no reviews for this product. Be the first to review Lenalidomide 4'-PEG3-amine and earn rewards!

Have you used Lenalidomide 4'-PEG3-amine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


TPD and Induced Proximity Research Product Guide

TPD and Induced Proximity Research Product Guide

This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:

  • Active Degraders
  • TAG Degradation Platform
  • Degrader Building Blocks
  • Assays for Protein Degradation
  • Induced Proximity Tools
Targeted Protein Degradation Poster

Targeted Protein Degradation Poster

Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia